Prevalence of depression and anxiety in systemic lupus erythematosus: a systematic review and meta-analysis by Lijuan Zhang et al.
RESEARCH ARTICLE Open Access
Prevalence of depression and anxiety in
systemic lupus erythematosus: a systematic
review and meta-analysis
Lijuan Zhang1,2, Ting Fu1,2, Rulan Yin1,2, Qiuxiang Zhang1,2 and Biyu Shen1*
Abstract
Background: Systemic lupus erythematosus (SLE) patients are at high risk for depression and anxiety. However,
the estimated prevalence of these disorders varies substantially between studies. This systematic review aimed to
establish pooled prevalence levels of depression and anxiety among adult SLE patients.
Methods: We systematically reviewed databases including PubMed, Embase, PsycINFO, and the Cochrane database
library from their inception to August 2016. Studies presenting data on depression and/or anxiety in adult SLE
patients and having a sample size of at least 60 patients were included. A random-effect meta-analysis was
conducted on all eligible data.
Results: A total of 59 identified studies matched the inclusion criteria, reporting on a total of 10828 adult SLE
patients. Thirty five and thirteen methods of defining depression and anxiety were reported, respectively. Meta-
analyses revealed that the prevalence of major depression and anxiety were 24% (95% CI, 16%-31%, I2 = 95.2%) and
37% (95% CI, 12%–63%, I2 = 98.3%) according to clinical interviews. Prevalence estimates of depression were 30%
(95% CI, 22%–38%, I2 = 91.6%) for the Hospital Anxiety and Depression Scale with thresholds of 8 and 39% (95% CI,
29%–49%, I2 = 88.2%) for the 21-Item Beck Depression Inventory with thresholds of 14, respectively. The main
influence on depression prevalence was the publication years of the studies. In addition, the corresponding pooled
prevalence was 40% (95% CI, 30%–49%, I2 = 93.0%) for anxiety according to the Hospital Anxiety and Depression
Scale with a cutoff of 8 or more.
Conclusions: The prevalence of depression and anxiety was high in adult SLE patients. It indicated that rheumatologists
should screen for depression and anxiety in their patients, and referred them to mental health providers in order to
identify effective strategies for preventing and treating depression and anxiety among adult SLE patients.
Trial registration: Current Meta-analysis PROSPERO Registration Number: CRD 42016044125. Registered 4 August 2016.
Keywords: Depression, Anxiety, Meta-analysis, Systematic review
Background
Systemic lupus erythematosus (SLE) is a multisystem,
autoimmune, connective-tissue disorder with frequent
psychological comorbidities, of which depression and
anxiety are two common manifestations [1, 2]. It has
been reported that there were 2 times higher prevalence
of depression in SLE patients compared to the general
population [3]. In addition, previous study has reported
that the anxiety disorders were twice as prevalent among
SLE patients as compared to the controls [4]. Depression
and anxiety often have profound impacts on SLE
patients’ health and well-being including increased inci-
dence of cardiovascular diseases [5], myocardial infarc-
tion [6], suicidal ideation [7], physical disability [8],
decreased quality of life [9, 10], and a higher risk of pre-
mature mortality [11]. Therefore, depression and anxiety
may be useful targets for interventions aimed at improv-
ing subjective health and quality of life in individuals
with SLE. However, current epidemiological evidence
found that the prevalence of depression and/or anxiety
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in SLE patients ranged widely from 2% to 91.7% in dif-
ferent studies [12, 13]. This vast inter-study difference
was previously attributed to multiple factors, including
study quality, unclear definition of depression or anxiety,
diverse screening strategies used across studies [14]. Re-
liable estimates of depression and anxiety prevalence are
important for informing efforts to prevent, treat, and
identify causes of depression and anxiety among SLE pa-
tients. Recent meta-analyses have estimated the overall
prevalence of depression and/or anxiety in rheumatoid
arthritis and osteoarthritis patients [14, 15]. There has
only been one previous systematic review of psychiatric
symptoms in SLE [16]; however, no systematic review
was conducted to quantify the prevalence of depression
and anxiety in SLE using meta-analysis techniques. Our
goal was to address this limitation. The objectives of this
systematic review were (i) to establish pooled prevalence
levels of depression and anxiety among adult SLE patients;
(ii) to provide a summary of the methods used to define
depression and anxiety in SLE; and (iii) to explore the im-
pacts of study characteristics on prevalence estimates.
Methods
This systematic review was conducted within the Reporting
Items for Systematic reviews and Meta-Analyses (PRISMA)
statement [17] and followed a predetermined registered
protocol (PROSPERO: CRD42016044125).
Search strategy
A systematic review of published literature in scientific
journals that reported on the prevalence of depression
and/or anxiety among SLE patients was conducted by
two independent reviewers using the following databases
from their inception to August 2016: PubMed, Embase,
PsycINFO, and the Cochrane database library. The
computer-based searches combined terms related to SLE
patients and study design with those related to depres-
sion or anxiety (see Additional file 1). We conducted cit-
ation chasing search strategy with all reference lists of
included articles and relevant review papers were con-
sidered to identify potentially omitted articles. Finally,
we corresponded with the authors for further informa-
tion if we encountered articles just provided the mean
and standard deviation of the depression and/or anxiety
assessment scale.
Inclusion and exclusion criteria
Studies were included if they met the following criteria:
(i) cross-sectional design, baseline cross-sectional data
from a longitudinal study or baseline cross-sectional
data from a trial, before group allocation; (ii) used vali-
dated methods (clinical interviews or self-report instru-
ments) to assess depression or anxiety; and (iii) the
sample size was no less than 60.
Case reports, review articles, animal studies, studies
investigating neuropsychiatric syndromes, studies in lan-
guages other than English and papers not dealing with
SLE patients were excluded. For this meta-analysis, stud-
ies using pediatrics sample or screening tools without
stating the cut-off thresholds used to detect depression
or anxiety were also excluded. Table 2 and Table 3 pre-
sented a full list of the eligible methods of detecting de-
pression and anxiety, alongside the numbers of articles
utilizing each method and the number of participants
assessed.
Data extraction and quality assessment
Two researchers read the relative studies independ-
ently by the titles and abstracts to exclude the refer-
ences which did not met the inclusion criteria. Then,
they read full texts in the remaining studies as men-
tioned above, and determined whether these refer-
ences included were final studies or not. When
multiple publications spanned the years of longitu-
dinal studies, baseline prevalence levels were reported.
The following information was independently ex-
tracted from each article by other two trained investi-
gators using a standardized form: year, country, mean
disease duration, percentage of female participants,
sample size, average age of participants, criteria for
detection of depression and anxiety, and reported
prevalence of depression and/or anxiety. If we en-
countered multiple publications from the same co-
hort, we used the data from the most recent or the
paper reporting data from the largest number of par-
ticipants. The methodological quality of each study
included in the present meta-analysis was assessed
using a modified version of the Newcastle-Ottawa
Scale [18]. Studies were judged to be at low risk of
bias (≥3 points) or high risk of bias (<3 points). Any
disagreements in data extraction and quality assess-
ment were resolved through discussion between the
two reviewers or adjudication with a third reviewer.
Outcome measures
The outcomes were major/minor depression and affective/
dysthymic/adjustment/anxiety disorder diagnosed with
a structured clinical assessment [e.g., Diagnostic and
Statistical Manual of Mental Disorders (DSM)-IV or
International Classification of Diseases (ICD)-10] or
depression and/or anxiety assessed with validated assess-
ment tools [e.g., the Hospital Anxiety and Depression
Scale (HADS), the Centre for Epidemiologic Studies
Depression Scale (CES-D)] (see Additional file 2).
Statistical analyses
Because random-effects models tended to provide wider
confidence intervals (CI) and were preferable in the
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presence of between-study heterogeneity, we used a
random-effects meta-analysis to pool studies reporting
the prevalence of depression and/or anxiety in SLE pa-
tients [19]. Between-study heterogeneity was assessed
by the I2 with thresholds of ≥25%, ≥50% and ≥75%
indicating low, moderate and high heterogeneity, re-
spectively [20]. The influence of individual study on
the overall prevalence estimate was explored by seri-
ally excluding each study in sensitivity analyses.
Wherever possible, subgroup analyses were planned
by overall study quality, sample size, country of origin
and publication year, if there was more than one
study in the subgroup. Pearson’s and Spearman’s cor-
relation analyses were used to assess the association
between variables and prevalence of depression and
anxiety in people with SLE. Funnel plots and Egger’s
test were combined to explore the potential publica-
tion bias in this meta-analysis [21, 22]. Statistical ana-
lyses were performed with STATA version 12.0.
Statistical tests were 2-sided and used a significance
threshold of P < 0.05.
Results
Search results
Fig. 1 provided the details of the study selection process.
The initial search identified a total of 3347 potentially
relevant articles. After removal of duplicates, titles and
then abstracts were screened for potential eligibility.
From this, 121 were considered in the full-text review,
of which 59 articles met the inclusion criteria, and a full
reference list was presented in Additional file 3. Inter-
rater reliability of reviewers regarding study relevancy
was high (Kappa = 0.87).
Study characteristics
A summary of the included study characteristics was
shown in Table 1. A total of 59 identified studies
matched the inclusion criteria, reporting on a total of
10828 adult SLE patients. Twenty took place in North
America, 18 in Asia, 12 in Europe, 6 in South America,
1 in Oceania, and 1 in Africa. The median of mean ages
was 39 years (range, 30.0-50.1), and the median percent-
age of females represented in the sample was 93%
Fig. 1 Search results and study selection
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(range, 75%–100%). In addition, the median number of
participants per study was 100 (range, 60–1827), and the
median of mean disease duration was 9 years (range,
0.22–16.3). Depression was defined in 35 different ways
(Table 2). Seventeen studies assessed for depression
using the 21 Item-Beck Depression Inventory (BDI),
with sixteen different thresholds were presented in the
articles. Thirteen articles used the CES-D; six different
cut-off points were presented, and the most commonly
used being 16. Twelve used the HADS with a cutoff of 8
or more, and 6 used other screening tools. Ten studies
assessed for major depression using diagnostic criteria
Table 2 Methods of detecting depression and summary of prevalence and heterogeneity findings
Tool Definition/cutoff No. of studies No. of participants Prevalence, % (95% CI) Heterogeneity I2, %
DSM and/or ICD
Major depressive disorder 10 2960 24 (16, 31) 95.2
Dysthymic disorder 6 922 12 (5, 18) 93.4
Adjustment disorder 2 280 20 (15, 24) 0.0
Minor depression 1 150 6 (2, 10) -
HADS ≥8 12 1474 30 (22, 38) 91.6
CES-D >10 1 344 55 (49, 60) -
≥16 8 1640 38 (32, 44) 81.3
>16.7 1 80 44 (33, 55) -
≥17 1 343 47 (42, 52) -
≥24 1 716 25 (22, 28) -
>27 1 93 16 (9, 24) -
21 Item-BDI ≥5 2 451 61 (56, 66) 17.7
≥10 1 167 21 (15, 27) -
≥11 1 81 35 (24, 45) -
≥13 1 63 24 (13, 34) -
≥14 6 781 39 (29, 49) 88.2
≥16 2 131 76 (45, 107) 95.4
≥17 1 103 40 (30, 49) -
≥18 1 127 42 (33, 50) -
≥19 1 100 21 (13, 29) -
≥20 2 213 50 (12, 89) 96.8
≥21 3 545 34 (2, 65) 98.8
≥29 1 153 19 (13, 25) -
≥30 3 326 5 (0, 9) 72.1
≥31 1 160 39 (31, 46) -
≥32 1 71 9 (3, 16) -
>40 1 160 21 (14, 27) -
HDS ≥8 1 126 41 (32, 49) -
≥11 1 62 45 (33, 58) -
≥16 1 126 2 (0, 5) -
>17 1 71 20 (10, 29) -
PHQ-9 ≥10 1 75 29 (19, 40) -
PHQ-2 ≥3 1 612 28 (25, 23) -
SCL-90-R 1 97 5 (1, 10) -
Zung SDS ≥53 1 156 33 (26, 41) -
DSM Diagnostic and Statistical Manual of Mental Disorders, ICD International Classification of Diseases, HADS Hospital Anxiety and Depression Scale, CES-D Centre
for Epidemiological Studies Depression Scale, BDI Beck Depression Inventory, HDS Hamilton Depression Scale, PHQ Patient Health Questionnaire, SCL-90-R
Symptoms Checklist-90-Revised, Zung SDS Zung Self-rating Depression Scale
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(DSM or ICD). The most commonly used screening
questionnaire to assess anxiety was the HADS, with 10
studies using this screening tool with thresholds of 8.
The methods employed to assess depression and anxiety
and the frequency of their use were presented in Table 2
and Table 3. When evaluated by Newcastle-Ottawa qual-
ity assessment criteria, out of 5 possible points, 2 studies
received 5 points, 7 received 4 points, 13 received 3
points, 36 received 2 points, and 1 received 1 point. The
details of the assessment of individual studies were
shown in Additional file 4.
Prevalence of depression among SLE patients
Prevalence estimates of depression ranged from 2% to
91.7% in individual studies (Table 1). Table 2 indicated
the summary of meta-analyses and heterogeneity assess-
ments. Meta-analyses revealed the prevalence of major
depressive disorder to be 24% (95% CI, 16%–31%) ac-
cording to the DSM and/or ICD diagnostic criteria, with
high heterogeneity (I2 = 95.2%). Prevalence estimates of
depression were 30% (95% CI, 22%–38%, I2 = 91.6%) for
the HADS with thresholds of 8 and 38% (95% CI, 32%–
44%, I2 = 81.3%) for the CES-D with thresholds of 16, re-
spectively. Prevalence of depression according to the 21
Item-BDI with a cutoff of 14 or more was 39% (95% CI,
29%–49%), with high heterogeneity (I2 = 88.2%) (Fig. 2).
Prevalence of anxiety among SLE patients
Prevalence of anxiety alone ranged between 4% and 85%
in individual studies (Table 1). Table 3 presented the
summary of meta-analyses and heterogeneity assess-
ments. Meta-analyses pooled the prevalence of anxiety
to be 40% (95% CI, 30%–49%, I2 = 93.0%) and 37%
(95% CI, 12%–63%, I2 = 98.3%) according to the
HADS with thresholds of 8 and the DSM and/or ICD
diagnostic criteria, respectively (Fig. 3).
Sensitivity and subgroup analyses
Table 4 suggested depression and anxiety prevalence es-
timates according to each sensitivity and subgroup ana-
lysis, in comparison with the primary analysis. Sensitivity
analyses revealed that the exclusion of studies with less
sample representativeness tended to decrease dysthymic
disorder prevalence estimates according to DSM and/or
ICD. The removal of studies with less comparable re-
spondent and non-respondent comparability tended to
increase depression prevalence estimates according to
the HADS with a cutoff of 8 or more. According to
DSM and/or ICD, anxiety prevalence estimates had a
trend to decrease by exclusion of studies only using fe-
male sample. The subgroup analyses were conducted ac-
cording to sample size, overall quality, publication year,
and country of origin. The results showed that studies
with sample size <200 had higher anxiety estimates [43%
(95% CI, 31%–55%) vs 28% (95% CI, 16%–40%)] accord-
ing to the HADS with a cutoff of 8 or more. When eval-
uated by Newcastle-Ottawa criteria, studies with lower
total overall quality scores yielded higher dysthymic dis-
order estimates [18% (95% CI, 6%–29%) vs 3% (95% CI,
2%–25%)] according to DSM and/or ICD. In contrast
with clinical interviews (DSM and/or ICD), more recent
publications tended to yield higher depression and anxiety
prevalence estimates according to self-report instruments.
The subgroup analyses for country of origin showed no
clear patterns. There was no particular trend or pattern in
any other sensitivity analyses or subgroup analyses.
Table 3 Methods of detecting anxiety and summary of prevalence and heterogeneity findings
Tool Definition/cutoff No. of studies No. of participants Prevalence, % (95% CI) Heterogeneity I2, %
DSM and/or ICD for anxiety disorder 5 663 37 (12, 63) 98.3
HADS ≥8 10 1332 40 (30, 49) 93.0
21 Item-BAI ≥8 2 313 71 (51, 91) 94
≥16 2 313 48 (39, 56) 59.2
≥26 2 313 18 (14, 22) 0
HAS ≥6 1 126 75 (67, 82) -
≥14 1 62 37 (25, 49) -
≥15 1 126 27 (19, 35) -
>17 1 71 24 (14, 34) -
Cattell questionnaire ≥21 1 166 85 (79, 90) -
SCL-90-R 1 97 4 (0, 8) -
Zung SAS >44 1 81 17 (9, 26) -
≥50 1 156 21 (14, 27) -
DSM Diagnostic and Statistical Manual of Mental Disorders, ICD International Classification of Diseases, HADS Hospital Anxiety and Depression Scale, BAI Beck
Anxiety Inventory, HAS Hamilton Anxiety Scale, SCL-90-R Symptoms Checklist-90-Revised, Zung SAS Zung Self-rating Anxiety Scale
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Associated study variables
We used Pearson’s and Spearmen’s correlation analyses
to assess the association between variables including
mean/medium disease duration, proportion of female
participants, mean/medium age, representativeness, sam-
ple size, comparability, overall quality, country of origin,
publication year, and the prevalence of depression and
anxiety. Table 5 indicated that more recent publications
was significantly associated with increased depression
prevalence (r = 0.26, P = 0.04). No study characteristics
presented a significant association with anxiety prevalence
estimate.
Assessment of publication bias
Assessment of publication bias indicated significant pub-
lication bias, according to the Egger’s test, in studies
reporting depression according to HADS with thresholds
of 8 and CES-D with a cutoff of 16 or more [Egger:
bias = 0.81 (95% CI: 0.04, 1.58), P = 0.04, and Egger:
bias = 2.79 (95% CI: 0.61, 4.97), P = 0.02, respectively].
There was no significant evidence of publication bias
in any other analyses (see Additional file 5).
Discussion
This systematic review and meta-analysis of 59 studies
involving 10828 adult SLE patients demonstrated that a
few studies using gold standard clinical interviews (DSM
and/or ICD) reported that major depression and anxiety
were presented in 24% and 37% among SLE patients, re-
spectively. The majority of studies using screening tools
found that significant depression were presented in 30%
using the HADS a cutoff of 8 or more and 39% using
Fig. 2 Prevalence of depressive disorder in SLE
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the 21 Item-BDI with thresholds of 14. This study also
found that more recent publications was significantly as-
sociated with increased depression prevalence among
SLE patients. Furthermore, the prevalence of anxiety was
40% according to the HADS with thresholds of 8. These
prevalence estimates are significantly higher than those
observed in the general population [23, 24] and other
rheumatic and connective tissue diseases [15, 25, 26].
Furthermore, these findings demonstrated that SLE pa-
tients tended to have a higher prevalence of anxiety than
depression, which was in line with previous studies
[27, 28]. Such discrepancy could be explained by the
differences in time frames when these studies were
performed, disease characteristics, social and cultural
contexts of the lupus patients and tools used for
assessing depression or anxiety. Because the develop-
ment of depression and/or anxiety could result in in-
creased incidence of cardiovascular diseases [5],
decreased quality of life [9, 10], and a higher risk of
premature mortality [11] among SLE patients, these
findings highlighted an important issue in health edu-
cation for this population.
Neuropsychiatric (NP) disorders appeared in about
70% of the patients diagnosed with SLE [29]. Previous
meta-analyses have assessed the prevalence of the 19
NP syndromes defined by the American College of
Rheumatology (ACR) in 1999 among SLE patients
[30]. However, there were a wide variety of neurologic
and psychiatric manifestations of SLE, which extended
beyond those identified in the 1999 ACR classification
criteria for SLE [31]. Several attempts have been
made to devise a classification of NP-SLE manifesta-
tions because there were controversies regarding the
inclusion of mood disorders in the 1999 ACR NP-SLE
criteria [31, 32]. That’s why we excluded the studies
investigating neuropsychiatric syndromes among SLE
patients in this meta-analysis.
Although studies varied widely in terms of quality, our
sensitivity analyses suggested that depression and/or
anxiety prevalence estimates (except dysthymic disorder
estimates) were reasonably stable. Variation in study
sample size contributed importantly to the observed het-
erogeneity in the data. Studies with sample size <200
had higher anxiety estimates according to the HADS
with thresholds of 8. Furthermore, studies with lower
total overall quality scores yielded higher dysthymic dis-
order estimates according to DSM and/or ICD. Country,
publication year, age, and gender also contributed to the
heterogeneity between studies.
In this meta-analysis, many methods were used for
data extraction and synthesis. The gold standard method
was diagnostic interviews using DSM or ICD criteria,
which were often time consuming and expensive. There-
fore, it was not ideal for examining patients in a busy
hospital environment [33]. Alternatively, self-report
screening tools might be used, because they were quick
Fig. 3 Prevalence of anxiety in SLE
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and easy to complete and cheaper to use than diag-
nostic interviews. However, prevalence estimates using
screening tools were often overestimated, because such
tools tended to prioritize sensitivity over specificity [33].
Furthermore, there have not been validation studies to de-
termine the best cut-point for screening tools in SLE pa-
tients, and several cut-off scores on self-report tools were
often used in many studies. It indicated that the rheuma-
tologists should always report prevalence at conventional
cut-points, and screen for depression and anxiety among
SLE patients according to the social and cultural contexts
of the rheumatologists and SLE patients in clinical
practice.
There are, however, additional important shortcom-
ings in the evidence on prevalence of depression in
SLE that need to be addressed. First, a substantial
amount of the heterogeneity among the studies
remained unexplained by the variables examined. Un-
examined factors, such as gender, age, disease dur-
ation, might contribute to the risk for depression
and/or anxiety symptom among SLE patients. Second,
the data were derived from studies that used different
designs and involved different groups of patients (e.g.,
from different countries), which might result in het-
erogeneity among the studies. Third, we did not look
for healthy subjects in each study reporting the preva-
lence of depression or anxiety in SLE patients, which
should be addressed in future research.
Conclusions
The prevalence of depression and anxiety was high in
adult SLE patients. It indicated that rheumatologists
should screen for depression and anxiety in their pa-
tients, and they should refer them to mental health pro-
viders in order to identify effective strategies for
preventing and treating depression and anxiety among
SLE patients.
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